Savara to host analyst and investor webinar on september 30, 2024

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, will host an analyst and investor webinar on september 30, 2024 from 8:30-9:30 a.m. et to present data from the phase 3 impala-2 clinical trial of molgramostim inhalation solution (molgramostim) in autoimmune pulmonary alveolar proteinosis (apap) and provide updates on the global commercial landscape and the company's market development work.
SVRA Ratings Summary
SVRA Quant Ranking